Literature DB >> 10673290

The human trefoil peptide, TFF1, is present in different molecular forms that are intimately associated with mucus in normal stomach.

J L Newton1, A Allen, B R Westley, F E May.   

Abstract

BACKGROUND: TFF1 is a 6.5 kDa secreted protein that is expressed predominantly in normal gastric mucosa. It is coexpressed with mucins and it can form dimers via a free carboxy terminal cysteine residue. AIMS: To investigate the molecular forms of TFF1 that are present in normal human stomach and the association of the different molecular forms with mucus.
SUBJECTS: All subjects had macroscopically normal stomachs at gastroscopy. None had a significant past medical history.
METHODS: TFF1 was detected in normal gastric mucosa and adherent mucus by western transfer analysis after electrophoresis on reducing and non-reducing polyacrylamide gels. In some instances, proteins were fractionated by caesium chloride density gradient centrifugation prior to detection of TFF1. The location of TFF1 in gastric mucosa with an intact adherent mucus layer was assessed by immunohistochemistry.
RESULTS: Three different molecular forms of TFF1 were detected: TFF1 monomer, TFF1 dimer, and a TFF1 complex with an apparent molecular mass of about 25 kDa. TFF1 was present at higher concentrations than realised previously. The TFF1 complex was present in the adherent mucus gel layer but while its interaction with mucin was destabilised by caesium chloride, the interaction between mucin and the TFF1 dimer was resistant to caesium chloride.
CONCLUSIONS: Most of TFF1 in normal human gastric mucosa is present in a complex that is stabilised by a disulphide bond. TFF1 is intimately associated with mucus. The high concentration, colocalisation, and binding of TFF1 to gastric mucus strongly implicate TFF1 in gastric mucus function.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10673290      PMCID: PMC1727855          DOI: 10.1136/gut.46.3.312

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  38 in total

1.  A colorimetric assay for glycoproteins based on the periodic acid/Schiff stain [proceedings].

Authors:  M Mantle; A Allen
Journal:  Biochem Soc Trans       Date:  1978       Impact factor: 5.407

2.  Mucus glycoprotein gels. Role of glycoprotein polymeric structure and carbohydrate side-chains in gel-formation.

Authors:  L A Sellers; A Allen; E R Morris; S B Ross-Murphy
Journal:  Carbohydr Res       Date:  1988-07-15       Impact factor: 2.104

3.  Sequence of the pS2 mRNA induced by estrogen in the human breast cancer cell line MCF-7.

Authors:  S B Jakowlew; R Breathnach; J M Jeltsch; P Masiakowski; P Chambon
Journal:  Nucleic Acids Res       Date:  1984-03-26       Impact factor: 16.971

4.  Breast cancer-associated pS2 protein: synthesis and secretion by normal stomach mucosa.

Authors:  M C Rio; J P Bellocq; J Y Daniel; C Tomasetto; R Lathe; M P Chenard; A Batzenschlager; P Chambon
Journal:  Science       Date:  1988-08-05       Impact factor: 47.728

5.  Antipeptide antibodies against the pNR-2 oestrogen-regulated protein of human breast cancer cells and detection of pNR-2 expression in normal tissues by immunohistochemistry.

Authors:  N H Piggott; J A Henry; F E May; B R Westley
Journal:  J Pathol       Date:  1991-02       Impact factor: 7.996

6.  Helicobacter pylori in vivo causes structural changes in the adherent gastric mucus layer but barrier thickness is not compromised.

Authors:  J L Newton; N Jordan; L Oliver; V Strugala; J Pearson; O F James; A Allen
Journal:  Gut       Date:  1998-10       Impact factor: 23.059

7.  Measurement of protein using bicinchoninic acid.

Authors:  P K Smith; R I Krohn; G T Hermanson; A K Mallia; F H Gartner; M D Provenzano; E K Fujimoto; N M Goeke; B J Olson; D C Klenk
Journal:  Anal Biochem       Date:  1985-10       Impact factor: 3.365

8.  [Primary structure of human protein pS2].

Authors:  M C Rio; P Lepage; P Diemunsch; C Roitsch; P Chambon
Journal:  C R Acad Sci III       Date:  1988

9.  hSP, the domain-duplicated homolog of pS2 protein, is co-expressed with pS2 in stomach but not in breast carcinoma.

Authors:  C Tomasetto; M C Rio; C Gautier; C Wolf; M Hareuveni; P Chambon; R Lathe
Journal:  EMBO J       Date:  1990-02       Impact factor: 11.598

10.  pNR-2/pS2 immunohistochemical staining in breast cancer: correlation with prognostic factors and endocrine response.

Authors:  J A Henry; N H Piggott; U K Mallick; S Nicholson; J R Farndon; B R Westley; F E May
Journal:  Br J Cancer       Date:  1991-04       Impact factor: 7.640

View more
  35 in total

1.  High expression of the trefoil protein TFF1 in interval breast cancers.

Authors:  M Crosier; D Scott; R G Wilson; C D Griffiths; F E May; B R Westley
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

2.  Selective gene expression by rat gastric corpus epithelium.

Authors:  M Goebel; A Stengel; N W G Lambrecht; G Sachs
Journal:  Physiol Genomics       Date:  2010-12-21       Impact factor: 3.107

Review 3.  Effect of age-related changes in gastric physiology on tolerability of medications for older people.

Authors:  Julia L Newton
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

4.  Heterodimeric interaction between GKN2 and TFF1 entails synergistic antiproliferative and pro-apoptotic effects on gastric cancer cells.

Authors:  Olga Kim; Jung Hwan Yoon; Won Suk Choi; Hassan Ashktorab; Duane T Smoot; Suk Woo Nam; Jung Young Lee; Won Sang Park
Journal:  Gastric Cancer       Date:  2017-02-01       Impact factor: 7.370

5.  Interleukin-8, cyclo-oxygenase-2, and trefoil factor family 1 gene expression and their association with Helicobacter pylori infection in the remnant stomach.

Authors:  Chengzhong Xing; Shunji Kato; Norio Matsukura; Noriko Matsuda; Huimian Xu; En Takashi; Nobutaka Yamada; Zenya Naito; Takashi Tajiri
Journal:  Surg Today       Date:  2005       Impact factor: 2.549

6.  Association of genetic variants with myocardial infarction in Japanese individuals with or without metabolic syndrome.

Authors:  Toshiki Kawamiya; Kimihiko Kato; Hideki Horibe; Kiyoshi Yokoi; Mitsutoshi Oguri; Tetsuro Yoshida; Tetsuo Fujimaki; Sachiro Watanabe; Kei Satoh; Yukitoshi Aoyagi; Yoshinori Nozawa; Toyoaki Murohara; Yoshiji Yamada
Journal:  Exp Ther Med       Date:  2010-09-10       Impact factor: 2.447

Review 7.  Structure, Function, and Therapeutic Potential of the Trefoil Factor Family in the Gastrointestinal Tract.

Authors:  Nayara Braga Emidio; Stuart M Brierley; Christina I Schroeder; Markus Muttenthaler
Journal:  ACS Pharmacol Transl Sci       Date:  2020-06-09

8.  Molecular forms of trefoil factor 1 in normal gastric mucosa and its expression in normal and abnormal gastric tissues.

Authors:  Jian-Lin Ren; Jin-Yan Luo; Ya-Pi Lu; Lin Wang; Hua-Xiu Shi
Journal:  World J Gastroenterol       Date:  2006-12-07       Impact factor: 5.742

9.  Systemically administered trefoil factors are secreted into the gastric lumen and increase the viscosity of gastric contents.

Authors:  S Kjellev; E Nexø; L Thim; S S Poulsen
Journal:  Br J Pharmacol       Date:  2006-07-31       Impact factor: 8.739

Review 10.  Improving the gastrointestinal tolerability of aspirin in older people.

Authors:  Julia L Newton
Journal:  Clin Interv Aging       Date:  2006       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.